Iopidine (Apraclonidine)

Apraclonidine acts as a selective alpha‑2 adrenergic receptor agonist in the eye. It decreases the production of aqueous humor and enhances uveoscleral outflow, resulting in a net reduction of intra‑ocular pressure, which is essential for glaucoma management.

The dosing regimen for Iopidine is determined by the prescribing clinician based on the patient’s condition and response. Typically, a single drop is instilled in the affected eye(s) once or twice daily, but the exact schedule should follow the prescriber’s instructions.

The pregnancy category for apraclonidine is unknown. Use during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant. Clinicians should evaluate each case individually and discuss alternatives when appropriate.

To order Iopidine, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative class includes prostaglandin analogues such as latanoprost, which primarily increase outflow of aqueous humor. Apraclonidine reduces aqueous production and modestly increases uveoscleral outflow. While prostaglandins are often first‑line, apraclonidine can be useful as adjunct therapy or when patients cannot tolerate prostaglandins.

Iopidine should be stored at room temperature, below 25 °C, in its original container. Protect the solution from light, moisture and extreme temperatures. Keep the bottle tightly closed when not in use to maintain sterility and potency.

Iopidine is applied as an ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid, and instill one drop into the conjunctival sac of the prescribed eye(s). Close the eye gently for a few seconds and avoid blinking excessively.

Serious risks include severe allergic reactions such as angioedema, systemic hypotension or bradycardia from systemic absorption, and acute ocular inflammation. Patients should seek immediate medical attention if they experience swelling of the face or throat, rapid heartbeat, dizziness, or sudden severe eye pain.

Iopidine is contraindicated in individuals with known hypersensitivity to apraclonidine or any component of the formulation. Caution is advised for patients with narrow‑angle glaucoma, severe cardiovascular disease, or those taking systemic adrenergic antagonists. Consultation with an eye care professional is essential before initiating therapy.